Relieves muscle spasm associated with acute, painful musculoskeletal conditions. ANDA 78722, held by Sun Pharm Inds Ltd. Cyclobenzaprine Hydrochloride.
As of Nov 16, 2026, ANDA 78722 (Cyclobenzaprine Hydrochloride), held by Sun Pharm Inds Ltd, was first approved by FDA on May 12, 2008, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 12, 2008 | Original application | Approved | None posted |
| Cyclobenzaprine Hydrochloride5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Discontinued |
| Cyclobenzaprine Hydrochloride7.5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Discontinued |
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Discontinued |
| Apr 11, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 12, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters